'Supermutators' found amongst highly levofloxacin-resistant E. coli isolates: A rapid protocol for the detection of mutation sites

Emerging Microbes and Infections

Volumn 4, Issue 1, 2015, Pages

  Zayed, Ahmed Abdel Fattah ^a   Essam, Tamer Mohamed ^b   Hashem, Abdel Gawad Mohamed ^b   El Tayeb, Ossama Mohamed ^b  

^a sixth of October City   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

AcrAB efflux pump; DNA gyrase; multiplex PCR sequencing; QRDR; topoisomerase IV

Indexed keywords

DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING) A; LEVOFLOXACIN; PROTEIN PARC; PROTEIN PARE; VIRULENCE FACTOR; ACRAB-TOLC PROTEIN, E COLI; ACRR PROTEIN, E COLI; ANTIINFECTIVE AGENT; BACTERIAL DNA; BACTERIAL PROTEIN; CARRIER PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; ESCHERICHIA COLI PROTEIN; MARR PROTEIN, E COLI; REPRESSOR PROTEIN; SOXR PROTEIN, BACTERIA; TRANSCRIPTION FACTOR;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL MUTATION; BACTERIUM ISOLATE; CONTROLLED STUDY; DISK DIFFUSION; DNA SEQUENCE; ESCHERICHIA COLI; GENOTYPE; HIGH THROUGHPUT SEQUENCING; LEVOFLOXACIN RESISTANT ESCHERICHIA COLI ISOLATE; MULTIPLEX POLYMERASE CHAIN REACTION; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ALIGNMENT; WILD TYPE; ANTIBIOTIC RESISTANCE; CHEMISTRY; DRUG EFFECTS; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MUTATION;

ESCHERICHIA COLI;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CARRIER PROTEINS; DISK DIFFUSION ANTIMICROBIAL TESTS; DNA GYRASE; DNA TOPOISOMERASE IV; DNA TOPOISOMERASES, TYPE II; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; HUMANS; LEVOFLOXACIN; MICROBIAL SENSITIVITY TESTS; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATION; REPRESSOR PROTEINS; TRANSCRIPTION FACTORS;

EID: 84927925445     PISSN: None     EISSN: 22221751     Source Type: Journal    
DOI: 10.1038/emi.2015.4     Document Type: Article

References (35)

1. Hooper DC. Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clin Infect Dis 2001; 32(Suppl 1): S9-S15.
2. Dalhoff A. Global Fluoroquinolone resistance epidemiology and implictions for clinical use. Interdiscip Perspect Infect Dis 2012; 2012: 976273.
3. Khawcharoenporn T, Vasoo S, Ward E, Singh K. High rates of quinolone resistance among urinary tract infections in the ED. Am J Emerg Med 2012; 30: 68-74.
4. Morgan-Linnell SK, Becnel Boyd L, Steffen D et al. Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. Antimicrob Agents Chemother 2009; 53 235-241.
5. Jacoby GA. Mechanisms of resistance to quinolones. Clin Infect Dis 2005; 41(Suppl 2): S120-S126.
6. Komp Lindgren P, Karlsson A, Hughes D. Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. Antimicrob Agents Chemother 2003; 47: 3222-3232.
7. Wang H, Dzink-Fox JL, Chen M et al. Genetic characterization of highly fluoroquinolone-resistant clinical Escherichia coli strains from China: role of acrR mutations. Antimicrob Agents Chemother 2001; 45: 1515-1521.
8. Maneewannakul K, Levy SB. Identification for mar mutants among quinolone-resistant clinical isolates of Escherichia coli. Antimicrob Agents Chemother 1996; 40: 1695-1698.
9. Koutsolioutsou A, Pena-Llopis S, Demple B. Constitutive soxR mutations contribute to multiple-antibiotic resistance in clinical Escherichia coli isolates. Antimicrob Agents Chemother 2005; 49: 2746-2752.
10. Barnard FM, Maxwell A. Interaction between DNA gyrase and quinolones: effects of alanine mutations at GyrA subunit residues Ser83 and Asp87. Antimicrob Agents Chemother 2001; 45: 1994-2000.
11. Heisig P. Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother 1996; 40: 879-885.
12. Koutsolioutsou A, Martins EA, White DG et al. A soxRS-constitutive mutation contributing to antibiotic resistance in a clinical isolate of Salmonella enterica (Serovar Typhimurium). Antimicrob Agents Chemother 2001; 45: 38-43.
13. Schneiders T, Amyes SGB, Levy SB. Role of AcrR and RamA in fluoroquinolone resistance in clinical Klebsiella pneumoniae isolates from Singapore. Antimicrob Agents Chemother 2003; 47: 2831-2837.
14. Cavaco LM, Frimodt-Møller N, Hasman H et al. Prevalence of quinolone resistance mechanisms and associations to minimum inhibitory concentrations in quinoloneresistant Escherichia coli isolated from humans and swine in Denmark. Microb Drug Resist 2008; 14: 163-169.
15. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, 22nd informational supplement. CLSI document M100-S22. Wayne, PA: CLSI, 2012. Available at http://www.indabook.org/preview/8gaxEopPrDb-fkWdELy71yeEBjeFu0sVzLyJn7c--eM,/M100-S22-Performance-Standards-for-Antimicrobial.html?query=M100-S22-Performance-Standards-for-Antimicrobial
16. Kronvall G. Normalized resistance interpretation as a tool for establishing epidemiological MIC susceptibility breakpoints. J Clin Microbiol 2010; 48: 4445-4452.
17. Aly MEA, Essam TM, Amin MA. Antibiotic resistance profile of E. coli strains isolated from clinical specimens and food samples in Egypt. Int J Microbiol Res 2012; 3: 176-182.
18. Aly MEA, Essam TM, Amin MA. Involvement of virulence genes and antibiotic resistance in clinical and food borne diarrheagenic Escherichia coli isolates from Egypt. World J Med Sci 2012; 7: 276-284.
19. Ye J, Coulouris G, Zaretskaya I et al. Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction. BMC Bioinformatics 2012; 13: 134.
20. Ma H, Difazio S. An efficient method for purification of PCR products for sequencing. BioTechniques 2008; 44: 921-923.
21. Yamaguchi Y, Nimbari S, Ookawara T et al. Inhibitory effects of agarose gel and LB medium on DNA sequencing. BioTechniques 2002; 33: 282, 284.
22. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 1977; 74: 5463-5467.
23. Sievers F, Wilm A, Dineen D et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol 2011; 7: 539.
24. Arsene S, Leclercq R. Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to floroquinolones. Antimicrob Agents Chemother 2007; 51: 3254-3258.
25. Singh R, Ledesma KR, Chang KT et al. Impact of recA on levofloxacin exposure-related resistance development. Antimicrob Agents Chemother 2010; 54: 4262-4268.
26. Fu Y, Zhang W, Wang H et al. Specific patterns of gyrA mutations determine the resistance difference to ciprofloxacin and levofloxacin in Klebsiella pneumoniae and Escherichia coli. BMC Infect Dis 2013; 13: 8.
27. Li J, Gao X, Luo T et al. Association of gyrA/B mutations and resistance levels to fluoroquinolones in clinical isolates of Mycobacterium tuberculosis. Emerg Microbes Infect 2014; 3: e19.
28. Oethinger M, Kern WV, Jellen-Ritter AS et al. Ineffectiveness of topoisomerase mutations in mediating clinically significant fluoroquinolone resistance in Escherichia coli in the absence of the AcrAB efflux pump. Antimicrob Agents Chemother 2000; 44: 10-13.
29. Webber MA, Talukder A, Piddock LJV. Contribution of mutation at amino acid 45 of AcrR to acrB expression and ciprofloxacin resistance in clinical and veterinary Escherichia coli isolates. Antimicrob Agents Chemother 2005; 49: 4390-4392.
30. Swick MC, Evangelista MA, Bodine TJ et al. Novel conserved genotypes correspond to antibiotic resistance phenotypes of E. coli clinical isolates. PLoS ONE 2013; 8: e65961.
31. Sulavik MC, Houseweart C, Cramer C et al. Antibiotic susceptibility profiles of Escherichia coli strains lacking multidrug efflux pump genes. Antimicrob Agents Chemother 2001; 45: 1126-1136.
32. Shigemura K, Tanaka K, Yamamichi F et al. Does mutation in gyrA and/or parC or efflux pump expression play the main role in fluoroquinolone resistance in Escherichia coli urinary tract infections?: a statistical analysis study. Int J Antimicrob Agents 2012; 40: 516-520.
33. Marcusson LL, Frimodt-Møller N, Hughes D. Interplay in the selection of fluoroquinolone resistance and bacterial fitness. PLoS Pathog 2009; 5: e1000541.
34. Paltansing S, Kraakman MEM, Ras JMC et al. Characterization of fluoroquinolone and cephalosporin resistance mechanisms in Enterobacteriaceae isolated in a Dutch teaching hospital reveals the presence of an Escherichia coli ST131 clone with a specific mutation in parE. J Antimicrob Chemother 2013; 68: 40-45.
35. Ciesielczuk H, Hornsey M, Choi Vet al. Development and evaluation of a multiplex PCR for eight plasmid-mediated quinolone-resistance determinants. J Med Microbiol 2013; 62(Pt 12): 1823-1827.